31 Recruiting Non-small Cell Lung Cancer (NSCLC) Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Non-small Cell Lung Cancer (NSCLC)
Related Conditions
Top Recruiting Non-small Cell Lung Cancer (NSCLC) Studies
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
📍 Kaiser Permanente - Oakland ( Site 0054) — Oakland, California
View Study & Checklist ➔HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
📍 UCLA — Santa Monica, California
View Study & Checklist ➔PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
📍 City of Hope — Duarte, California
View Study & Checklist ➔Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
📍 University of Birmingham Alabama — Birmingham, Alabama
View Study & Checklist ➔Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
📍 UCLA Hematology/Oncology - Santa Monica ( Site 0023) — Los Angeles, California
View Study & Checklist ➔Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
📍 Florida Cancer Specialists & Research Institute — Fleming Island, Florida
View Study & Checklist ➔Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
📍 Henry Ford Health — Detroit, Michigan
View Study & Checklist ➔Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
📍 ArriVent Investigative Site — Prescott, Arizona
View Study & Checklist ➔Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
📍 Highlands Oncology Group — Springdale, Arkansas
View Study & Checklist ➔Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
📍 Mayo Clinic in Arizona - Phoenix ( Site 0147) — Phoenix, Arizona
View Study & Checklist ➔Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
📍 Research Site — Chandler, Arizona
View Study & Checklist ➔Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
📍 Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center — Fullerton, California
View Study & Checklist ➔Pembrolizumab for Advanced NSCLC and PS 2-3
📍 Mount Sinai Hospital — New York, New York
View Study & Checklist ➔A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
📍 Southern Cancer Center Pc — Daphne, Alabama
View Study & Checklist ➔A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
📍 Sansum Clinic — Santa Barbara, California
View Study & Checklist ➔Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
📍 UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
View Study & Checklist ➔A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
📍 Southern Cancer Center Pc — Daphne, Alabama
View Study & Checklist ➔Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
📍 UCLA — Los Angeles, California
View Study & Checklist ➔Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
📍 Compassionate Cancer Care Center — Fountain Valley, California
View Study & Checklist ➔Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
📍 University of California, Davis Comprehensive Cancer Center — Sacramento, California
View Study & Checklist ➔Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
📍 Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) — Nashville, Tennessee
View Study & Checklist ➔A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
📍 Oncura Health d.b.a.Los Angeles Cancer Network — Glendale, California
View Study & Checklist ➔